Key Takeaway: Protara Therapeutics has announced its financial results for Q2 2026 and provided updates on its clinical trials. The company expects to complete enrollment for the BCG-Unresponsive cohort of the ADVANCED-2 trial by the fourth quarter of 2026. Additionally, the ADVANCED-3 trial is being redesigned to focus on high-grade, high-risk patients.
Market Sentiment Analysis
POSITIVE FACTORS
Protara Therapeutics is progressing with the ADVANCED-2 trial.
Enrollment completion is expected in Q4 2026.
The ADVANCED-3 trial is being redesigned to enhance data collection.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+147%
120-day peak, hindsight
Typical move
11.7%
average across 4 past catalysts
Cash runway
~22 mo
Low dilution risk
Lead asset
TARA-002
Phase 3 · Bladder (Urothelial, Transitional Cell) Cancer
Full Press Release Details
Expect to complete enrollment of the BCG-Unresponsive registrational cohort of the ADVANCED-2 trial in 4Q 2026 The ADVANCED-3 trial is being redesigned as an exploratory trial to expand into and accelerate data in high-grade, high-risk BCG-Naïve and BCG-Exposed CIS (± Ta/T1) patients and papillary
Frequently Asked Questions
What are the financial results for Protara in Q2 2026?
Protara Therapeutics announced its financial results for the second quarter of 2026.
When will enrollment for the ADVANCED-2 trial be completed?
Enrollment for the BCG-Unresponsive cohort of the ADVANCED-2 trial is expected to complete in Q4 2026.
What changes are being made to the ADVANCED-3 trial?
The ADVANCED-3 trial is being redesigned as an exploratory trial to focus on high-risk patients.